
    
      This multicenter observer-blind study will determine the safety and reactogenicity of GSK
      Biologicals' investigational HIV vaccine 732462 in two sequentially enrolling cohorts of
      HIV-infected subjects treated with HAART (highly active antiretroviral therapy) and HIV
      infected treatment na√Øve subjects, respectively.
    
  